The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 45 | 20.3x | 20.1x | Near average | |
Growth | 46 | 2.8% | 5.6% | Near average | |
Quality | 74 | 20.2% | 7.6% | Above average | |
Safety | 53 | 1.8x | 0.4x | Near average | |
Capital Return | 21 | — | 2.19% | Below average | |
Momentum | 65 | — | — | Near average | |
Sentiment | 34 | — | — | Below average |
Novartis AG is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Novartis AG shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Novartis stock saw stability in its average price target at 141 dollars over the past week, despite the number of analysts contributing to the estimates doubling from 3 to 6, indicating a growing consensus around this valuation. Looking at the longer term (30 days), we find an improvement in expectations by 3.68% compared to a previous average of 136 dollars, reflecting a slight positive revision in the outlook of financial institutions over the past month.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.